TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 36647781

Group type: EXPERIMENTAL
Intervention: Proteasome inhibitor (PI) regimen
Number of subjects: 454

Group type: EXPERIMENTAL
Intervention: Immunomodulatory drug (IMiD) regimen
Number of subjects: 454

Group type: EXPERIMENTAL
Intervention: PI+IMiD-based regimen
Number of subjects: 454

Group type: EXPERIMENTAL
Intervention: Conventional regimen
Number of subjects: 454

Group type: EXPERIMENTAL
Intervention: Autologous stem cell transplantation (ASCT) during first-line therapy
Number of subjects: 454

Group type: EXPERIMENTAL
Intervention: Novel agent-based regimens
Number of subjects: 454

Group type: EXPERIMENTAL
Intervention: Sustained MRD negativity
Number of subjects: 454
Study: 36648035

Group type: EXPERIMENTAL
Intervention: Definity microbubbles infusion (2 vials diluted in 50 mL of saline; infusion rate: 4-10 mL/min)
Number of subjects: 56
Study: 36648039

Group type: EXPERIMENTAL
Intervention: Blood-Oxygen-Level Dependent (BOLD) T2-Mapping
Number of subjects: 0
Study: 36648054

Group type: EXPERIMENTAL
Intervention: Atherosclerotic MINOCA (Ath-MINOCA)
Number of subjects: 190

Group type: COMPARATOR
Intervention: Nonatherosclerotic MINOCA (non-Ath-MINOCA)
Number of subjects: 190

Group type: EXPERIMENTAL
Intervention: Atherosclerotic cause
Number of subjects: 190
Study: 36648132

Group type: EXPERIMENTAL
Intervention: Replication-defective herpes simplex virus (HSV) 2 vaccine
Number of subjects: 0
Study: 36648215

Group type: EXPERIMENTAL
Intervention: Neoadjuvant treatment (various strategies including immunotherapies, chemotherapy, targeted treatments)
Number of subjects: 402

Group type: EXPERIMENTAL
Intervention: Neoadjuvant treatment (various strategies)
Number of subjects: 402

Group type: COMPARATOR
Intervention: Neoadjuvant targeted treatment with dabrafenib and trametinib
Number of subjects: 402

Group type: EXPERIMENTAL
Intervention: Neoadjuvant immunotherapy with talimogene laherparepvec
Number of subjects: 402

Group type: COMPARATOR
Intervention: Neoadjuvant immunotherapy (combined ipilimumab and nivolumab)
Number of subjects: 402

Group type: COMPARATOR
Intervention: Neoadjuvant combination treatment
Number of subjects: 402

Group type: COMPARATOR
Intervention: Neoadjuvant HDI plus chemotherapy
Number of subjects: 402
Study: 36648249

Group type: EXPERIMENTAL
Intervention: Intermittently Scanned Continuous Glucose Monitoring
Number of subjects: 0
Study: 36648259

Group type: EXPERIMENTAL
Intervention: Increased miR-145 expression at T2
Number of subjects: 124

Group type: EXPERIMENTAL
Intervention: Increased miR-145 expression greater than 0.222 at T2
Number of subjects: 124

Group type: COMPARATOR
Intervention: No miRNAs
Number of subjects: 124
Study: 36648260

Group type: EXPERIMENTAL
Intervention: ARN-FI group
Number of subjects: 76
Study: 36648467

Group type: EXPERIMENTAL
Intervention: Torsemide (n=1431)
Number of subjects: 2859

Group type: COMPARATOR
Intervention: Furosemide (n=1428)
Number of subjects: 2859

Group type: EXPERIMENTAL
Intervention: Torsemide (n=536)
Number of subjects: 2859

Group type: COMPARATOR
Intervention: Furosemide (n=577)
Number of subjects: 2859
Study: 36648542

Group type: EXPERIMENTAL
Intervention: Endoscopic mucosal ischemic index (EMII) positivity on postoperative day 1 (POD 1)
Number of subjects: 58
Study: 36648553

Group type: COMPARATOR
Intervention: Roux-en-Y gastric bypass
Number of subjects: 32

Group type: COMPARATOR
Intervention: Surgical groups (Roux-en-Y gastric bypass, sleeve gastrectomy)
Number of subjects: 32

Group type: COMPARATOR
Intervention: Post-bariatric hypoglycaemia
Number of subjects: 32

Group type: COMPARATOR
Intervention: Other hormonal responses
Number of subjects: 32
Study: 36648594

Group type: EXPERIMENTAL
Intervention: Bimekizumab 320 mg Q4W
Number of subjects: 108

Group type: COMPARATOR
Intervention: Ustekinumab (45/90 mg weight-based at baseline and week 4, then every 12 weeks)
Number of subjects: 108

Group type: COMPARATOR
Intervention: Placebo (Q4W through week 16, then bimekizumab 320 mg Q4W)
Number of subjects: 108
Study: 36648627

Group type: EXPERIMENTAL
Intervention: Molnupiravir 800 mg twice daily for 5 days
Number of subjects: 55

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 55

Group type: EXPERIMENTAL
Intervention: Molnupiravir
Number of subjects: 55
Study: 36648744

Group type: EXPERIMENTAL
Intervention: High-dose IND/LNG-IUS 8 (15.4 mg IND)
Number of subjects: 174

Group type: EXPERIMENTAL
Intervention: Middle-dose IND/LNG-IUS 8 (12.5 mg IND)
Number of subjects: 174

Group type: EXPERIMENTAL
Intervention: Low-dose IND/LNG-IUS 8 (6.5 mg IND)
Number of subjects: 174

Group type: COMPARATOR
Intervention: LNG-IUS 8 (control group, 13.5 mg LNG)
Number of subjects: 174

Group type: EXPERIMENTAL
Intervention: Low- and middle-dose IND/LNG-IUS 8
Number of subjects: 174
Study: 36648926

Group type: EXPERIMENTAL
Intervention: Bilateral deep brain stimulation (DBS) of the medial geniculate body (MGB)
Number of subjects: 6
Study: 36648999

Group type: EXPERIMENTAL
Intervention: Automated convolutional neural network (CNN) approach using Dixon-based MRI
Number of subjects: 136
Study: 36649008

Group type: EXPERIMENTAL
Intervention: Tigulixostat 50 mg
Number of subjects: 143

Group type: EXPERIMENTAL
Intervention: Tigulixostat 100 mg
Number of subjects: 143

Group type: EXPERIMENTAL
Intervention: Tigulixostat 200 mg
Number of subjects: 143

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 143

Group type: EXPERIMENTAL
Intervention: Tigulixostat (all doses)
Number of subjects: 143
Study: 36649068

Group type: EXPERIMENTAL
Intervention: Technology-Enabled Collaborative Care (TECC) model for diabetes management and mental health support
Number of subjects: 30
Study: 36649072

Group type: EXPERIMENTAL
Intervention: Anti-PD-1 therapy
Number of subjects: 1
Study: 36649086

Group type: EXPERIMENTAL
Intervention: Early expansion of CD36- nonclassical monocytes on day 1 (D1)
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: Natural killer cells on day 3 (D3)
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: Follicular T helper cells from day 1 to day 3 (D1-D3)
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: Plasma cells on day 3 (D3)
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: Plasma cell expansion on day 3 (D3)
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: Increased plasma cell maturation on days 11-14 (D11-D14)
Number of subjects: 15
Study: 36649152

Group type: EXPERIMENTAL
Intervention: Transdermal alcohol biosensors (TAC)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Blood biomarkers (PEth)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Self-report (TLFB)
Number of subjects: 0
Study: 36649157

Group type: EXPERIMENTAL
Intervention: Group CBT
Number of subjects: 66

Group type: EXPERIMENTAL
Intervention: Group MBCT
Number of subjects: 66
Study: 36649192

Group type: EXPERIMENTAL
Intervention: Lateral pelvic lymph node dissection after preoperative chemoradiotherapy (n = 139)
Number of subjects: 409

Group type: COMPARATOR
Intervention: Lateral pelvic lymph node dissection without preoperative chemoradiotherapy (n = 270)
Number of subjects: 409

Group type: EXPERIMENTAL
Intervention: Lateral pelvic lymph node dissection after preoperative chemoradiotherapy
Number of subjects: 409
Study: 36649248

Group type: EXPERIMENTAL
Intervention: Total nitrites (tertile 3 vs. 1)
Number of subjects: 104168

Group type: EXPERIMENTAL
Intervention: Foods and water-originated nitrites (tertile 3 vs. 1)
Number of subjects: 104168

Group type: EXPERIMENTAL
Intervention: Additives-originated nitrites (higher consumers vs. non-consumers)
Number of subjects: 104168

Group type: EXPERIMENTAL
Intervention: Sodium nitrite (e250, higher consumers vs. non-consumers)
Number of subjects: 104168

Group type: COMPARATOR
Intervention: Total, foods and water-originated, or additives-originated nitrates
Number of subjects: 104168
Study: 36649339

Group type: EXPERIMENTAL
Intervention: High-dose oxytocin titration regimen (initial-incremental rate of 6 milliunits/min)
Number of subjects: 955

Group type: COMPARATOR
Intervention: Standard-dose titration regimen (initial-incremental rate of 2 milliunits/min)
Number of subjects: 955

Group type: EXPERIMENTAL
Intervention: Oxytocin dose rates exceeding 20 milliunits/min
Number of subjects: 955

Group type: COMPARATOR
Intervention: Oxytocin dose rates at 20 milliunits/min or less
Number of subjects: 955
Study: 36649389

Group type: EXPERIMENTAL
Intervention: Biodegradable polymer ultrathin-strut sirolimus-eluting Orsiro stent (O-SES)
Number of subjects: 2521

Group type: COMPARATOR
Intervention: Biodegradable polymer biolimus-eluting Nobori stent (N-BES)
Number of subjects: 2521

Group type: EXPERIMENTAL
Intervention: O-SES
Number of subjects: 2521

Group type: COMPARATOR
Intervention: N-BES
Number of subjects: 2521

Group type: EXPERIMENTAL
Intervention: O-SES (within the first year)
Number of subjects: 2521

Group type: COMPARATOR
Intervention: N-BES (within the first year)
Number of subjects: 2521

Group type: EXPERIMENTAL
Intervention: O-SES (from 1 to 5 years)
Number of subjects: 2521

Group type: COMPARATOR
Intervention: N-BES (from 1 to 5 years)
Number of subjects: 2521
Study: 36649484

Group type: EXPERIMENTAL
Intervention: Dapagliflozin
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 0
Study: 36649570

Group type: EXPERIMENTAL
Intervention: Adjuvant anthracycline-based chemotherapy followed by tamoxifen endocrine therapy for 5 years
Number of subjects: 283

Group type: COMPARATOR
Intervention: Tamoxifen alone
Number of subjects: 283
Study: 36649686

Group type: EXPERIMENTAL
Intervention: Online ERP therapy
Number of subjects: 224

Group type: COMPARATOR
Intervention: Online psychoeducation
Number of subjects: 224
Study: 36649694

Group type: EXPERIMENTAL
Intervention: Ticagrelor monotherapy
Number of subjects: 1329

Group type: COMPARATOR
Intervention: Ticagrelor plus aspirin
Number of subjects: 1329
Study: 36649713

Group type: EXPERIMENTAL
Intervention: High-performance liquid chromatography-tandem mass spectrometry assay for 3,3'-Cl 2 BPA-G and 3,3'-Cl 2 BPA-S quantification in plasma samples.
Number of subjects: 0
Study: 36649753

Group type: EXPERIMENTAL
Intervention: Counterweight-Plus Programme (CWP)
Number of subjects: 35

Group type: COMPARATOR
Intervention: Usual Care (UC)
Number of subjects: 35
Study: 36649998

Group type: EXPERIMENTAL
Intervention: D2 lymphadenectomy with No. 14v lymph node dissection
Number of subjects: 0

Group type: COMPARATOR
Intervention: D2 lymphadenectomy without No. 14v lymph node dissection
Number of subjects: 0
Study: 36650011

Group type: EXPERIMENTAL
Intervention: HPV screening
Number of subjects: 903

Group type: COMPARATOR
Intervention: Cytology
Number of subjects: 903
Study: 36650020

Group type: EXPERIMENTAL
Intervention: Tasquinimod
Number of subjects: 0
Study: 36650254

Group type: EXPERIMENTAL
Intervention: Online Behavioural Activation (BA) with therapist support
Number of subjects: 17

Group type: COMPARATOR
Intervention: Online Behavioural Activation (BA) without therapist support
Number of subjects: 17
Study: 36650328

Group type: EXPERIMENTAL
Intervention: Home BP measurement
Number of subjects: 510

Group type: EXPERIMENTAL
Intervention: Clinic BP measurement
Number of subjects: 510

Group type: EXPERIMENTAL
Intervention: Kiosk BP measurement
Number of subjects: 510

Group type: COMPARATOR
Intervention: ABPM (24-h ambulatory BP monitoring)
Number of subjects: 510
Study: 36650329

Group type: EXPERIMENTAL
Intervention: Yoga
Number of subjects: 120

Group type: COMPARATOR
Intervention: Education
Number of subjects: 120
Study: 36650357

Group type: EXPERIMENTAL
Intervention: Resin-based Y90 radioembolization (low/scout activity of 555 MBq)
Number of subjects: 30
Study: 36650405

Group type: EXPERIMENTAL
Intervention: LARS score questionnaire
Number of subjects: 222
Study: 36650435

Group type: EXPERIMENTAL
Intervention: Laryngeal mask airway (LMA)
Number of subjects: 58

Group type: COMPARATOR
Intervention: Deep extubation (ETT Group)
Number of subjects: 58
Study: 36650458

Group type: EXPERIMENTAL
Intervention: Focused metacognitive intervention (MCG)
Number of subjects: 43

Group type: COMPARATOR
Intervention: Treatment as usual (Control)
Number of subjects: 43
Study: 36650502

Group type: EXPERIMENTAL
Intervention: Trauma-focused therapy (TFT) + treatment as usual (TAU)
Number of subjects: 158

Group type: COMPARATOR
Intervention: Treatment as usual (TAU)
Number of subjects: 158
Study: 36650593

Group type: EXPERIMENTAL
Intervention: EIT-guided PEEP titration
Number of subjects: 0

Group type: COMPARATOR
Intervention: High-PEEP/FiO2 tables
Number of subjects: 0
Study: 36650958

Group type: EXPERIMENTAL
Intervention: SET-ULM (Spatial Exploration Test of Upper Limb Mobility)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Motor Function Measure (MFM)
Number of subjects: 30
Study: 36651161

Group type: EXPERIMENTAL
Intervention: Somapacitan 0.16 mg/kg/week
Number of subjects: 62

Group type: EXPERIMENTAL
Intervention: Somapacitan 0.20 mg/kg/week
Number of subjects: 62

Group type: EXPERIMENTAL
Intervention: Somapacitan 0.24 mg/kg/week
Number of subjects: 62

Group type: COMPARATOR
Intervention: Daily GH 0.035 mg/kg/day
Number of subjects: 62

Group type: COMPARATOR
Intervention: Daily GH 0.067 mg/kg/day
Number of subjects: 62

Group type: EXPERIMENTAL
Intervention: Somapacitan (all doses)
Number of subjects: 62

Group type: COMPARATOR
Intervention: Daily GH (both doses)
Number of subjects: 62
Study: 36651370

Group type: EXPERIMENTAL
Intervention: Neoveil (polyglycolic acid)
Number of subjects: 45

Group type: COMPARATOR
Intervention: TachoSil (collagen sponge)
Number of subjects: 45
Study: 36651481

Group type: EXPERIMENTAL
Intervention: Metabolic Syndrome (MetS)
Number of subjects: 18264

Group type: EXPERIMENTAL
Intervention: Pre-frailty
Number of subjects: 18264

Group type: EXPERIMENTAL
Intervention: Frailty
Number of subjects: 18264

Group type: EXPERIMENTAL
Intervention: Co-existent MetS with pre-frailty/frailty
Number of subjects: 18264

Group type: COMPARATOR
Intervention: MetS alone
Number of subjects: 18264
Study: 36651601

Group type: EXPERIMENTAL
Intervention: bDMARDs (biologic disease-modifying antirheumatic drugs)
Number of subjects: 532
Study: 36651624

Group type: EXPERIMENTAL
Intervention: Cognitive-behavioral therapy (CBT) - 16 1-hour sessions
Number of subjects: 131

Group type: EXPERIMENTAL
Intervention: Medication (duloxetine 30-60 mg/day or escitalopram 10-20 mg/day)
Number of subjects: 131

Group type: COMPARATOR
Intervention: Both CBT and medication
Number of subjects: 131

Group type: EXPERIMENTAL
Intervention: Cognitive-behavioral therapy (CBT)
Number of subjects: 131

Group type: COMPARATOR
Intervention: Medication
Number of subjects: 131
Study: 36651820

Group type: EXPERIMENTAL
Intervention: Once-weekly semaglutide 1.0 mg
Number of subjects: 3534

Group type: COMPARATOR
Intervention: Matched placebo
Number of subjects: 3534
Study: 36651866

Group type: EXPERIMENTAL
Intervention: Women
Number of subjects: 4499

Group type: EXPERIMENTAL
Intervention: Women in general wards (GWs)
Number of subjects: 4499

Group type: EXPERIMENTAL
Intervention: Women in ICU
Number of subjects: 4499

Group type: EXPERIMENTAL
Intervention: Acute heart failure (AHF)
Number of subjects: 4499

Group type: EXPERIMENTAL
Intervention: Acute kidney injury (AKI)
Number of subjects: 4499

Group type: EXPERIMENTAL
Intervention: Acute respiratory failure (ARF)
Number of subjects: 4499

Group type: EXPERIMENTAL
Intervention: Female sex in general wards (GWs)
Number of subjects: 4499

Group type: EXPERIMENTAL
Intervention: Female sex in ICU
Number of subjects: 4499
Study: 36651955

Group type: EXPERIMENTAL
Intervention: Conservative treatment via a rehabilitation program and antiplatelet therapy
Number of subjects: 49

Group type: EXPERIMENTAL
Intervention: ECV (extracellular volume fraction)
Number of subjects: 49
Study: 36651958

Group type: EXPERIMENTAL
Intervention: Live-video mind-body program for stress management and resiliency
Number of subjects: 220
Study: 36651961

Group type: EXPERIMENTAL
Intervention: Intravenous V937 (1 × 10) and ipilimumab, up to 8 cycles of V937, median of 6 injections of V937 and 3.5 infusions of ipilimumab
Number of subjects: 11
Study: 36651990

Group type: EXPERIMENTAL
Intervention: Mycoprotein (240 g/day)
Number of subjects: 20

Group type: COMPARATOR
Intervention: High red and processed meat diet
Number of subjects: 20
Study: 36652004

Group type: EXPERIMENTAL
Intervention: Modified serial surgical techniques 'ASTRO'
Number of subjects: 24
Study: 36652022

Group type: EXPERIMENTAL
Intervention: Autologous fibrin glue
Number of subjects: 61

Group type: COMPARATOR
Intervention: Sutures
Number of subjects: 61
Study: 36652082

Group type: EXPERIMENTAL
Intervention: Subcutaneous ICD devices under battery advisory
Number of subjects: 1054
Study: 36652106

Group type: EXPERIMENTAL
Intervention: Technosphere insulin (TI) - individualized single preprandial dose of TI (4-12 U, in 4-U increments) via oral inhalation.
Number of subjects: 27
Study: 36652155

Group type: EXPERIMENTAL
Intervention: Surgical resection
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Non-surgical local therapies (thermal ablation, hepatic arterial infusion pump (HAIP), stereotactic body radiation therapy (SBRT))
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Stereotactic body radiation therapy (SBRT)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Metastasis-directed therapy
Number of subjects: 0
Study: 36652175

Group type: EXPERIMENTAL
Intervention: Amivantamab
Number of subjects: 0

Group type: COMPARATOR
Intervention: Real-World Clinical Practice (RWCP) treatments
Number of subjects: 0
Study: 36652223

Group type: EXPERIMENTAL
Intervention: Mavacamten
Number of subjects: 251
Study: 36652281

Group type: EXPERIMENTAL
Intervention: Young Person's Face IT (YPF), a self-guided web-based intervention
Number of subjects: 71
Study: 36652284

Group type: EXPERIMENTAL
Intervention: eOncoNote plus usual methods of communication
Number of subjects: 173

Group type: COMPARATOR
Intervention: Usual communication only
Number of subjects: 173
Study: 36652352

Group type: EXPERIMENTAL
Intervention: Aspirin (81 mg twice daily)
Number of subjects: 12211

Group type: COMPARATOR
Intervention: Low-molecular-weight heparin (enoxaparin, 30 mg twice daily)
Number of subjects: 12211
Study: 36652353

Group type: EXPERIMENTAL
Intervention: Bivalent BA.1 (30 μg)
Number of subjects: 1846

Group type: EXPERIMENTAL
Intervention: Bivalent BA.1 (60 μg)
Number of subjects: 1846

Group type: EXPERIMENTAL
Intervention: Monovalent BA.1 (60 μg)
Number of subjects: 1846

Group type: COMPARATOR
Intervention: BNT162b2 (30 μg)
Number of subjects: 1846

Group type: EXPERIMENTAL
Intervention: Bivalent BA.1 (30 μg and 60 μg) and Monovalent BA.1 (60 μg)
Number of subjects: 1846
Study: 36652354

Group type: EXPERIMENTAL
Intervention: Futibatinib
Number of subjects: 103
Study: 36652465

Group type: EXPERIMENTAL
Intervention: SGLT-2 inhibitors
Number of subjects: 716

Group type: COMPARATOR
Intervention: Other oral hypoglycemic agents
Number of subjects: 716
Study: 36652665

Group type: EXPERIMENTAL
Intervention: Docetaxel plus carboplatin
Number of subjects: 54

Group type: COMPARATOR
Intervention: Epirubicin/cyclophosphamide followed by docetaxel
Number of subjects: 54

Group type: EXPERIMENTAL
Intervention: High HRD scores (≥ 38)
Number of subjects: 54

Group type: EXPERIMENTAL
Intervention: BRCA1/2 mutations
Number of subjects: 54
Study: 36652687

Group type: EXPERIMENTAL
Intervention: Recovery-Oriented Community Navigation Service
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 0
Study: 36653029

Group type: EXPERIMENTAL
Intervention: Two-dose mumps-containing vaccine (MuCV)
Number of subjects: 105
Study: 36653035

Group type: EXPERIMENTAL
Intervention: Probiotic supplement
Number of subjects: 60

Group type: COMPARATOR
Intervention: Indistinguishable placebo
Number of subjects: 60
Study: 36653060

Group type: EXPERIMENTAL
Intervention: 56 Gy of radiation to the inguinal site and concurrent cisplatin chemotherapy
Number of subjects: 157
Study: 36653065

Group type: EXPERIMENTAL
Intervention: Cooled radiofrequency treatment
Number of subjects: 49

Group type: COMPARATOR
Intervention: Conventional radiofrequency treatment
Number of subjects: 49
Study: 36653167

Group type: EXPERIMENTAL
Intervention: Cognitive behavioural therapy for social anxiety
Number of subjects: 96

Group type: COMPARATOR
Intervention: Cognitive remediation
Number of subjects: 96
Study: 36653241

Group type: EXPERIMENTAL
Intervention: Encorafenib plus Cetuximab (doublet therapy)
Number of subjects: 220
Study: 36653533

Group type: EXPERIMENTAL
Intervention: CSII + CGM
Number of subjects: 481

Group type: COMPARATOR
Intervention: CSII only
Number of subjects: 481

Group type: COMPARATOR
Intervention: Overall (CSII only and CSII + CGM)
Number of subjects: 481
Study: 36653578

Group type: EXPERIMENTAL
Intervention: New equations for estimated cardiorespiratory fitness (eCRF)
Number of subjects: 92

Group type: EXPERIMENTAL
Intervention: Objectively measured cardiorespiratory fitness
Number of subjects: 92
Study: 36653595

Group type: EXPERIMENTAL
Intervention: Intravitreal aflibercept (IVT-AFL) treatment
Number of subjects: 0
Study: 36653750

Group type: EXPERIMENTAL
Intervention: Ultrasound-derived bilateral anterior thigh thickness (BATT)
Number of subjects: 223
Study: 36653768

Group type: EXPERIMENTAL
Intervention: Integrated care strategy including rifampicin treatment daily for four months, follow-up by nursing personnel, general practitioners, specialists, and other professionals, along with transportation and food assistance.
Number of subjects: 300

Group type: COMPARATOR
Intervention: Isoniazid treatment received by a cohort of children between 2015 and 2018 following the standardized scheme in Colombia.
Number of subjects: 300
Study: 36653786

Group type: EXPERIMENTAL
Intervention: Infection phase
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Recovery phase
Number of subjects: 100
Study: 36653812

Group type: EXPERIMENTAL
Intervention: Hypovolemic phlebotomy and usual care
Number of subjects: 440

Group type: COMPARATOR
Intervention: Usual care alone
Number of subjects: 440
Study: 36653848

Group type: EXPERIMENTAL
Intervention: Atezolizumab-vemurafenib-cobimetinib
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Vemurafenib-cobimetinib
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Dabrafenib-plus-trametinib
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Encorafenib-plus-binimetinib
Number of subjects: 0
Study: 36653858

Group type: EXPERIMENTAL
Intervention: Exercise therapy and self-management support (12 weeks: 18 60-min group-based and 6 home-based sessions; 6 90-min group-based sessions) supervised by physiotherapists
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Exercise therapy and self-management support
Number of subjects: 20
Study: 36653872

Group type: EXPERIMENTAL
Intervention: AB-free kava
Number of subjects: 80

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 80
Study: 36655056

Group type: EXPERIMENTAL
Intervention: 400 mg celecoxib per day
Number of subjects: 140

Group type: COMPARATOR
Intervention: Matching placebo
Number of subjects: 140
Study: 36655338

Group type: EXPERIMENTAL
Intervention: DREAMLAND (psychological mobile application)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 60